Topic: Parkinson's disease
In roundworm models of Parkinson's, probiotic Bacillus subtilis lowered the buildup of alpha-synuclein in the brain—a culprit in the disease.
The CK1 inhibitor passed tests in healthy volunteers at Pfizer before getting derailed by the Big Pharma’s retreat from neuroscience R&D in 2018.
Medtronic received a CE mark for a deep brain stimulation system that can not only deliver electrical therapy but also record the brain’s signals.
Kyowa Kirin won FDA approval for istradefylline as an add-on treatment for Parkinson’s disease in August, more than 10 years after it was handed a thumbs-down in 2008 and six years after it got its Japanese go-ahead.
Parkinson's patients in a trial of Novartis' Tasigna showed a boost in dopamine that may have halted the decline of motor and non-motor functions.
A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.
A new study out of the Mount Sinai Icahn School of Medicine identifies the gene STMN2 as a key regulator of Parkinson’s disease.
As each company works to cut costs and stay alive, Acorda will lay off about one-quarter of its employees, while Alkermes will cut 160 jobs.
Stanford scientists have identified a molecular defect in Parkinson’s disease and pinpointed a promising drug candidate to target it.
Terazosin, a decades-old drug for enlarged prostate, appears to improve Parkinson's symptoms, tests in animal models and a large patient database show.